Inside digital health’s H1 funding landscape

The latest stories trending on MedCity News.

Editor's Pick

Top Story Digital Health's H1 Funding Landscape: Slimmer Checks, Fewer Deals & a Smaller Investor Pool The digital health sector has entered a new era when it comes to funding, and startups in this space must quickly adjust to an investment landscape that is characterized by lower check sizes, fewer deals and smaller cohort of investors. If things continue at the pace the sector has maintained throughout the first half of the year, 2023 will mark the field's lowest yearly fundraising total since 2019, according to a new report. Sponsorship Post PE Investments, Acquisitions Fuel New Stages of Growth for Healthcare and Life Science Companies Presented by West Monroe In an interview, Nathan Ray, a partner with the healthcare and life practice who oversees M&A/PE related work in that industry for West Monroe, highlighted how his firm works with companies to drive due diligence for clients, and help acquired companies address issues and differentiate during holds. Learn More>> Speakers Revealed INVEST Digital Health 2023 This year's event is covering many themes from Responsible AI to Solving Pharma's Pain Points to Reducing Friction between Payers and Providers, and so much more. Join us to hear from innovative investors, prominent industry players, contrarians, and entrepreneurs offering novel approaches to healthcare's greatest challenges. October 26th at Pegasus Park in Dallas, TX. Reserve Your Seat for Only $295 [sale ends 7/28] - Register Now!

Featured News

RA Capital Leads $150M Financing for Septerna and Lead Drug With Oral Edge in Rare Hormone Disease Septerna Therapeutics' Series B financing will support plans to reach the clinic with a pill for a rare disease whose only approved therapy is a Takeda Pharmaceutical drug that's leaving the market. Potential rival therapies are all injectables. Humana Report: Health-related Social Needs Prevalent Among Dual-eligible and Non-dual-eligible MA Enrollees A Humana study in Health Affairs found that 80% of dual-eligible beneficiaries had at least one health-related social need in 2019, compared to 48% of non-dual-eligible enrollees. While prevalence was higher in dual-eligible enrollees, non-dual-eligible enrollees shouldn't be overlooked, researchers said. Report: Those With Limited English Proficiency Are More Likely to be Uninsured Of nonelderly people with limited English proficiency in 2021, 29% were uninsured, versus 9% of English proficient people, according to a new KFF analysis. Hospitals Have Concerns About CMS' Proposed $9B Lump Sum Payment for Illegal 340B Cuts CMS recently proposed a $9 billion lump sum payment to remedy illegal payment cuts for 340B drugs from 2018 to 2022. In general, hospital groups have reacted positively to the fact that 340B providers will receive lump sum payments but have expressed concern about CMS' methods for maintaining budget neutrality with this plan. J&J Gets Foothold in Head & Neck Cancer With Deal for Nanobiotix's Lead Program Johnson & Johnson is committing up to $60 million for global rights to a Nanobiotix therapy that enhances radiation treatment for head and neck cancer. A Phase 3 test of the nanoparticle-based therapy is expected to yield preliminary data in 2024.

Resources

Sponsored Content Introducing Payer's Place, a Video Interview Series Highlighting Healthcare Payer Executive Perspectives Presented by HLTH and MedCity News We're proud to introduce Payer's Place, a series of video interviews spotlighting perspectives from senior payer executives. The series will share insights from payers based on developments and trends they've seen in the healthcare industry and what keeps them up at night. Kicking off the series are interviews with executives from Humana and SCAN  Health Plan, which are available to view on demand in the HLTH Community. Click here to learn more!

MedCity News • PO Box 901 • New York, NY unsubscribe